Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fc gamma R engagement and type I interferon signaling

Yofe, I; Landsberger, T; Yalin, A; Solomon, I; Costoya, C; Demane, DF; Shah, M; David, E; Borenstein, C; Barboy, O; Matos, I; Peggs, KS; Quezada, SA; Amit, I

Amit, I (通讯作者),Weizmann Inst Sci, Dept Syst Immunol, Rehovot, Israel.;Quezada, SA (通讯作者),UCL, Res Dept Haematol, Canc Immunol Unit, Canc Inst, London, England.

NATURE CANCER, 2022; 3 (11): 1336

Abstract

Despite the clinical success of checkpoint inhibitors, a substantial gap still exists in our understanding of their mechanism of action. While antibod......

Full Text Link